NASDAQ:SMMT Summit Therapeutics (SMMT) Stock Price, News & Analysis $7.24 +0.35 (+5.08%) (As of 07/5/2024 08:53 PM ET) Add Compare Share Share Today's Range$6.90▼$7.3450-Day Range$2.39▼$10.9252-Week Range$1.52▼$11.25Volume1.97 million shsAverage Volume3.19 million shsMarket Capitalization$5.08 billionP/E RatioN/ADividend YieldN/APrice Target$13.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Summit Therapeutics alerts: Email Address Summit Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside86.5% Upside$13.50 Price TargetShort InterestBearish28.15% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.26) to ($0.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.17 out of 5 starsMedical Sector750th out of 879 stocksPharmaceutical Preparations Industry348th out of 417 stocks 3.5 Analyst's Opinion Consensus RatingSummit Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSummit Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Summit Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted28.15% of the float of Summit Therapeutics has been sold short.Short Interest Ratio / Days to CoverSummit Therapeutics has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Summit Therapeutics has recently increased by 10.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSummit Therapeutics does not currently pay a dividend.Dividend GrowthSummit Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SMMT. Previous Next 2.5 News and Social Media Coverage News SentimentSummit Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Summit Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 18 people have searched for SMMT on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows10 people have added Summit Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 11% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Summit Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders88.30% of the stock of Summit Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.61% of the stock of Summit Therapeutics is held by institutions.Read more about Summit Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Summit Therapeutics are expected to decrease in the coming year, from ($0.26) to ($0.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Summit Therapeutics is -45.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Summit Therapeutics is -45.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSummit Therapeutics has a P/B Ratio of 65.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Summit Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… Click here to register now. About Summit Therapeutics Stock (NASDAQ:SMMT)Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.Read More SMMT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SMMT Stock News HeadlinesJuly 7 at 2:20 AM | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $6.89July 3, 2024 | businesswire.comSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 8, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… July 1, 2024 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Up 4.1%June 17, 2024 | fool.com3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall StreetJune 3, 2024 | businesswire.comSummit Raises $200 Million; Also Expands License Territories for IvonescimabJune 1, 2024 | businesswire.comIvonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMAMay 31, 2024 | businesswire.comIvonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus ChemotherapyJuly 8, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… May 31, 2024 | seekingalpha.comSummit Therapeutics Stock: Plunging Despite A Win?May 30, 2024 | businesswire.comSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 30, 2024 | reuters.comSummit Therapeutics cancer therapy succeeds in late-stage China studyMay 30, 2024 | businesswire.comIvonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in ChinaMay 28, 2024 | fool.comWhy Summit Therapeutics Stock Is Sinking TodayMay 24, 2024 | finance.yahoo.comSummit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment AnnouncedMay 8, 2024 | seekingalpha.comSummit: A Few Catalysts In Q2 Of 2024 To Carry The TideMay 7, 2024 | msn.comSummit spikes as Citi launches at Buy on lead assetMay 2, 2024 | finance.yahoo.comSummit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call TranscriptSee More Headlines Receive SMMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today7/08/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SMMT CUSIPN/A CIK1599298 Webwww.summitplc.com Phone650-460-8308Fax44-12-3544-3999Employees105Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$14.00 Low Stock Price Target$13.00 Potential Upside/Downside+86.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-614,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-125.07% Return on Assets-51.02% Debt Debt-to-Equity Ratio2.26 Current Ratio6.97 Quick Ratio6.97 Sales & Book Value Annual Sales$700,000.00 Price / Sales7,260.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book65.82Miscellaneous Outstanding Shares701,980,000Free Float82,132,000Market Cap$5.08 billion OptionableOptionable Beta-0.97 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Robert W. Duggan (Age 79)Co-CEO & Executive Chairman Dr. Mahkam Zanganeh D.D.S. (Age 54)M.B.A., Co-CEO, President & Director Comp: $657.81kMr. Ankur Dhingra (Age 47)Chief Financial Officer Comp: $530kMr. Manmeet Singh Soni (Age 46)COO & Director Comp: $591.5kProf. Dame Kay Davies DBE (Age 73)FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor Ms. Abby Guzman MurphyHead of Human ResourcesMs. Divya Chari (Age 56)Head of Global Clinical Operations Mr. Dave GancarzChief Business & Strategy Officer?Mr. Will BlackHead of Information Technology?Dr. Betty Y. Chang Ph.D.Head of Research, Oncology & Inflammation?More ExecutivesKey CompetitorsTeva Pharmaceutical IndustriesNYSE:TEVAGenmab A/SNASDAQ:GMABBioMarin PharmaceuticalNASDAQ:BMRNRoyalty PharmaNASDAQ:RPRXSarepta TherapeuticsNASDAQ:SRPTView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 3,846 shares on 5/20/2024Ownership: 0.003%California State Teachers Retirement SystemSold 5,603 shares on 5/16/2024Ownership: 0.020%Alpine Global Management LLCBought 5,000 shares on 5/15/2024Ownership: 0.005%Price T Rowe Associates Inc. MDBought 5,139 shares on 5/15/2024Ownership: 0.005%Shell Asset Management Co.Sold 3,301 shares on 5/14/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions SMMT Stock Analysis - Frequently Asked Questions How have SMMT shares performed this year? Summit Therapeutics' stock was trading at $2.61 on January 1st, 2024. Since then, SMMT stock has increased by 177.4% and is now trading at $7.24. View the best growth stocks for 2024 here. How were Summit Therapeutics' earnings last quarter? Summit Therapeutics Inc. (NASDAQ:SMMT) posted its earnings results on Wednesday, May, 1st. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. When did Summit Therapeutics IPO? Summit Therapeutics (SMMT) raised $40 million in an initial public offering on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager. How do I buy shares of Summit Therapeutics? Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Summit Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Summit Therapeutics investors own include Energy Transfer (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), CBL & Associates Properties (CBL) and SandRidge Permian Trust (PER). This page (NASDAQ:SMMT) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SMMT Stock Alerts